🔎 Trials Near Me

Pradžia › Ūmi mieloidinė leukemija › Ilinoisas › Chicago

Ūmi mieloidinė leukemija klinikiniai tyrimai Chicago, IL

26 tyrimai dėl Ūmi mieloidinė leukemija ieško dalyvių vietose Chicago ir aplinkui (apytiksliai 30 mylių spinduliu). Atidarykite tyrimą, kad pamatytumėte, kas gali dalyvauti ir kaip susisiekti su tyrimo komanda.

Oficialus tyrimo tekstas (anglų kalba)

Ieškote dalyvių tyrimui? Pateikite jį šio puslapio viršuje – $99 už 30 dienų →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
  • Mount Sinai Hospital Medical Center, Chicago
  • John H Stroger Jr Hospital of Cook County, Chicago
  • University of Illinois, Chicago
  • ir dar 1
Amžius nuo 40 iki 75 · Visoms lytims · Atnaujinta 2026-10-02 · NCT05334069

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Renkami dalyviai1 fazė
  • University of Chicago Comprehensive Cancer Center, Chicago
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT06484062

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Renkami dalyviai2 fazė
  • Northwestern University, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Amžius nuo 18 iki 59 · Visoms lytims · Atnaujinta 2026-09-28 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Renkami dalyviai3 fazė
  • University of Chicago Medicine, Chicago
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Renkami dalyviai2 fazė
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • ir dar 1
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Renkami dalyviai2 fazė
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Renkami dalyviai2 fazė
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Renkami dalyviai2 fazė
  • Northwestern University, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Amžius nuo 18 iki 59 · Visoms lytims · Atnaujinta 2026-09-22 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Renkami dalyviai3 fazė
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
6 Months – 21 Years · Visoms lytims · Atnaujinta 2026-09-17 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Renkami dalyviai1/2 fazė
  • The University of Chicago Medical Center, Chicago
30 Days · Visoms lytims · Atnaujinta 2026-09-16 · NCT04065399

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

Renkami dalyviai1/2 fazė
  • University of Chicago, Chicago
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-11 · NCT06969430

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Renkami dalyviai3 fazė
  • Lurie Children's Hospital-Chicago, Chicago
Amžius nuo 1 iki 25 · Visoms lytims · Atnaujinta 2026-09-04 · NCT07022678

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Renkami dalyviai3 fazė
  • US-Chigago IL-UHCHICAGO, Chicago
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-01 · NCT07223814

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

Renkami dalyviai1 fazė
  • University of Chicago Comprehensive Cancer Center, Chicago
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-08-25 · NCT05886049

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Renkami dalyviai1/2 fazė
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Iki 22 metų · Visoms lytims · Atnaujinta 2026-08-25 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Renkami dalyviai3 fazė
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
  • Comer Children's Hospital, Chicago
29 Days – 21 Years · Visoms lytims · Atnaujinta 2026-08-24 · NCT05183035

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Renkami dalyviai1 fazė
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-20 · NCT06001788

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Renkami dalyviaiStebimasis tyrimas
  • Northwestern Memorial Hospital, Chicago
  • Rush University Medical Center, Chicago
  • University of Illinois at Chicago, Chicago
  • ir dar 2
Visi amžiai · Visoms lytims · Atnaujinta 2026-07-06 · NCT01351545

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Renkami dalyviai1 fazė
  • University of Chicago, Chicago
Amžius 13 ir vyresni · Visoms lytims · Atnaujinta 2026-05-05 · NCT04771572

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Renkami dalyviai1/2 fazė
  • Northwestern University, Chicago
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-13 · NCT05732103

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Renkami dalyviai1/2 fazė
  • Northwestern, Chicago
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-03-24 · NCT04988555

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Renkami dalyviai1 fazė
  • Northwestern Medicine, Chicago
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-03-16 · NCT06994676

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Renkami dalyviai1 fazė
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-13 · NCT05735184

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

Renkami dalyviai1 fazė
  • Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-09-24 · NCT06501196

Ūmi mieloidinė leukemija tyrimai kituose miestuose

Kiti tyrimai Chicago

Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.